EGFR and non-small cell lung carcinoma: While initially highly effective in appropriately selected NSCLC populations, durable long term responses to first generation EGFR inhibitors such as erlotinib are relatively uncommon, and most patients invariably progress to drug-resistant disease, typically within ~12 months3,25,26.